Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour
13. November 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4...
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update
06. November 2024 16:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today reported financial results for the quarter ended September 30, 2024, and provided a business update.
Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association Dermatology
19. September 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
ZORYVE® (roflumilast) cream 0.15% improved atopic dermatitis (AD) across multiple efficacy endpoints while demonstrating favorable safety and tolerabilityAcross both studies, approximately 31% of...
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
09. Juli 2024 16:53 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis announced the FDA approval for ZORYVE (roflumilast) cream, 0.15%, for the treatment of atopic dermatitis
Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
09. Juli 2024 08:00 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update
14. Mai 2024 16:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today reported financial results for the quarter ended March 31, 2024, and provided a business update.
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
10. März 2024 16:00 ET
|
Arcutis Biotherapeutics, Inc.
Investigational roflumilast cream 0.05% met the primary endpoint and all secondary endpoints, showing significant improvement
Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
04. März 2024 16:00 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the closing of its previously announced underwritten public offering.
Arcutis to Present at the TD Cowen 44th Annual Health Care Conference
29. Februar 2024 17:00 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis Announces Pricing of $150 Million Public Offering
28. Februar 2024 23:30 ET
|
Arcutis Biotherapeutics, Inc.
Arcutis today announced the pricing of its underwritten public offering of common stock.